Mutual Pharmaceutical Co. v. Bartlett
The Court ruled that federal law blocks a New Hampshire jury verdict against a generic drug manufacturer, because the only way the company could have satisfied the state's safety standard was to change its warning label -- something federal law forbids generic makers from doing on their own.
The decision extends the Court's 2011 ruling shielding generic manufacturers from failure-to-warn lawsuits to also cover design-defect lawsuits, making it far harder for patients hurt by generic drugs to sue when the drug's formula cannot be changed.
“When federal law forbids an action that state law requires, the state law is “without effect.””
The Court's core reasoning for why the state design-defect claim could not stand.
How it got here: A federal jury awarded the woman over $21 million on her design-defect claim; the First Circuit affirmed; Mutual asked the Supreme Court to review the preemption question.
The Case in Depth
What happened
A woman in New Hampshire was prescribed a brand-name pain reliever but received a generic version, sulindac, made by Mutual Pharmaceutical. She suffered a severe, disfiguring skin reaction that left her nearly blind and covered in burn-like wounds over much of her body. She sued Mutual, arguing the drug's design was unreasonably dangerous under state law given its risks compared to its benefits.
The question before the Court
Can a generic drug maker be sued under state law for having an unsafe design, when federal law bars it from changing the drug's formula or its warning label?
The Court's answer
No — federal law prevents such a lawsuit from succeeding. The Court ruled that New Hampshire's design-defect standard, as applied here, effectively required Mutual to strengthen sulindac's warning label, since the drug's simple chemistry and federal rules made redesigning it impossible. But federal regulations, as the Court had already held in PLIVA v. Mensing, bar generic drug manufacturers from unilaterally changing their labels.
Because Mutual could not legally take the one step that would have satisfied the state-law safety standard, complying with both state and federal law was physically impossible. Under the Supremacy Clause, a state law that puts a company in that bind is invalid, so the jury's $21 million verdict for the injured patient could not stand, and the case was reversed.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
People injured by generic drugs -- roughly 80% of prescriptions filled in the U.S. -- may now have no state-court remedy when the drug's design can't be altered and the fix would require a label change, since federal rules prevent generic makers from unilaterally changing labels or formulas. Generic manufacturers gain broad protection from this category of lawsuit.
What changes now
This is a final merits ruling reversing the jury verdict in the woman's favor; she is left without a remedy under this theory. The decision leaves open whether design-defect claims that track the federal misbranding statute might survive preemption, and does not address brand-name drugs, whose manufacturers can unilaterally update labels. Future suits against generic manufacturers over drug design will face a high preemption barrier.
What this does not decide
The Court expressly did not decide whether state design-defect claims that mirror the federal misbranding statute (which can require pulling a dangerous drug from the market) are preempted, since the jury here was never asked to find misbranding. The ruling is also limited to generic drugs, not brand-name drugs whose makers can change labels unilaterally.
Concurrences and dissents
Dissent — Justice Breyer
Justice Breyer argued it was not literally impossible for Mutual to comply with both laws, since it could have paid damages or exited the New Hampshire market; the real question was whether state law posed an obstacle to federal goals. He would have deferred to the FDA's views but found the agency's positions too inconsistent and undeveloped to carry weight here, and concluded there was no genuine conflict.
Dissent — Justice Sotomayor
Justice Sotomayor argued the majority wrongly recast a design-defect claim as a disguised failure-to-warn claim, when New Hampshire law never actually required Mutual to change its label -- it only required paying damages or leaving the market if the drug was unreasonably dangerous. She would have found no impossibility and preserved the jury verdict, warning the ruling grants pharmaceutical companies broad immunity Congress never intended.
How the Court got there
The legal reasoning, step by step
- The Court applied impossibility preemption, the rule that a state law is invalid when it is physically impossible for a company to follow both that law and a conflicting federal requirement at the same time.
- New Hampshire's design-defect standard asks a jury to weigh a product's usefulness and danger against the adequacy of its warning label, meaning a manufacturer can satisfy the standard either by redesigning the drug or by strengthening its warnings.
- Redesigning sulindac was not a real option: federal law requires generic drugs to keep the same active ingredients and formula as their brand-name counterparts, and the drug's simple, single-molecule chemistry left no room to alter it anyway.
- With redesign off the table, the only way Mutual could have satisfied New Hampshire's standard was to strengthen sulindac's warning label.
- But the Court's 2011 decision in PLIVA v. Mensing already held that federal regulations bar generic drug makers from independently changing their labels, so Mutual was legally forbidden from taking the one action that could have avoided liability.
- Because it was impossible to comply with both the state duty to improve the label and the federal duty to keep it the same, the Court held New Hampshire's warning-based design-defect claim was preempted, rejecting the argument that Mutual could have avoided the conflict simply by pulling the drug from the market entirely.
Doctrinal impact
Cases affected by this decision
Reaffirms PLIVA, Inc. v. Mensing (564 U. S. ___)
The Court relies on and extends this ruling that federal law bars generic label changes, to cover design-defect claims too.
Distinguishes Bates v. Dow Agrosciences LLC (544 U. S. 431)
The Court says this pesticide-labeling case does not undercut its holding because it involved a different express-preemption question.